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I. Introduction 
 The United States Patent and Trademark Office (USPTO) 
issues patents as a means of protecting the intellectual property for 
the inventors of medical devices such as hip arthroplasty implants 
that fulfill the requirement of being both useful1 and novel.2 
However, patents are issued for these devices prior to undergoing 
regulatory evaluation by the United States Food and Drug 
Administration (FDA) to establish their safety and their 
effectiveness. Furthermore, one of the main mechanisms the FDA 
has utilized for the evaluation of safety and effectiveness is the 
510(k) process, which allows regulatory approval based on a device 
being “substantially equivalent” to a device that had previously been 
granted FDA approval.3 Consequently, the USPTO is providing 
patent protection for medical devices that have not had their utility 
established because their safety and clinical effectiveness have not 
been confirmed by the regulatory process, and their novelty is 
questionable because the regulatory approval relies upon a 
demonstration of “substantial equivalence”4 to a previously 
approved implantable device. The problem with the current timeline 
of the patent process and subsequent regulatory evaluation of 
medical devices has been demonstrated in recent years by the 
extensive litigation involving metal-on-metal total hip implants. The 
patenting and regulatory evaluation processes must be modified so 
that the utility and novelty of medical devices is established before 
such devices receive intellectual property protection by the patent 
process. 
                                                 
1 35 U. S. C. § 101 (2006). 
2 35 U.S. C. § 102 (2011). 
3 21 USC 360c (2017), Notes of Decisions “Premarket approval.” 
4 Id. 
2https://open.mitchellhamline.edu/cybaris/vol9/iss2/4
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 In order to realize the impact of this issue on society as a 
whole and on the medical device manufacturing industry in 
particular, one must understand the procedure of total hip 
replacement (THR)5 and its related technology. This will be 
reviewed first. 
 Armed with an understanding of the medical procedure and 
the associated medical devices that are implanted in patients during 
the process, the procedures for protecting the associated intellectual 
property of the devices will next be reviewed. 
 Following this the regulatory evaluation process of the FDA 
will be examined. Dissecting this process will demonstrate the 
dichotomy that currently exists between the protection of intellectual 
property afforded by the USPTO and the clinical evaluation 
mechanism of the FDA. 
 Next, the recent litigation involving metal-on-metal hip 
implants will be discussed with a particular emphasis on the 
associated costs and societal impacts. Part of this discourse will 
include a consideration of the policy arguments of the interplay 
between intellectual property protection and the regulation and 
evaluation of that property.  
 The discourse will conclude with consideration of the options 
by which the process may be overhauled and with specific 
recommendations on the best course of action. 
                                                 
5 This procedure, at times, will also be referred to as “total hip 
arthroplasty” or “THA.” 
3Published by Mitchell Hamline Open Access, 2018
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 II. Total Hip Replacement Surgery History 
 The development of medical devices has had a dramatic 
socioeconomic impact on the health of citizens of the United States.  
The vast majority of these important discoveries have been 
developed within the last one hundred years.  One of the most 
significant medical devices developed in the mid-twentieth century 
is the modern, low-friction total hip arthroplasty.6  It is one of the 
few medical devices that has resulted in both an improvement in the 
quality of life, due to decreased pain and increased activity for 
patients as well as decreased mortality of patients when compared to 
age matched controls of patients who have not undergone the 
operation.7 The evolution of this operation and the associated 
implantable medical devices has had a significant impact on the lives 
of millions of individuals in the United States and around the world. 
                                                 
6 See JOHN CHARNLEY, LOW FRICTION ARTHROPLASTY 
OF THE HIP: THEORY AND PRACTICE (Springer-Verlag 1979). 
7 Jane Barrett et al, Survival Following Total Hip Replacement, 
87(9), J Bone Joint Surg Am, September 2005 at 1965. 
4https://open.mitchellhamline.edu/cybaris/vol9/iss2/4
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 Modern hip arthroplasty is generally attributed to the efforts 
of the British surgeon Sir John Charnley in the early 1960’s.8 
Charnley’s hip design involved a metallic head articulating on a 
plastic acetabular component.9 About the same time Charnley was 
developing a metal-on-plastic hip another designer, George McKee, 
began developing hip arthroplasty components that utilized a metal 
head articulating on a metal acetabular component.10 This device 
was patented in the United States in 1972.11 The timing of these 
developments—especially the efforts of George McKee--are 
particularly important because they pre-date the advent of the 
Medical Devices Act of 1976. Over the ensuing sixty years, there 
has been an intensive debate about which of the types of components 
is the safest and most effective. 
 During the last decade, extensive and expensive product 
liability litigation of the metal-on-metal type of implant may have 
effectively resolved this debate.12 
                                                 
8 Stephen R. Knight, Randeep Aujla, and Satya Prasad Biswas, Total 
Hip Arthroplasty – over 100 years of operative history, Orthop Rev. 
v. 3(2), Sep. 6, 2011; 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3257425/. 
9 JOHN CHARNLEY, supra note 12 at 41. Charnley’s initial hip 
design actually used a Teflon acetabular component, but he 
subsequently abandoned this bearing surface when it did not perform 
as mechanically anticipated. 
10 G. K. McKee, Development of Total Prosthetic Replacement of 
the Hip, 72, Clin Orthop, September-October 1970, at 85. 
11 U.S. Patent No. 3801989 A (filed Oct. 30, 1972). 
12 See In Re: DePuy Orthopaedics, Inc., ASR Hip Implant Products 
Liability Litigation, 753 F. Supp. 2d 1378 (MDL, 2010). 
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 A. Technology      
 Hip arthroplasty surgery is performed through one of several 
surgical approaches in patients and takes about one and one-half 
hours to accomplish.13  During the process, the surgeon moves 
between or cuts through the muscles of the hip, opens the capsule of 
tissue around the hip, and dislocates or pops the ball of the upper 
femur (head) out of the socket of the pelvis (acetabulum). The 
femoral head is removed with a saw. The acetabulum is prepared 
with a series of spherical, cheese-grater like instruments 
progressively increasing in size. A type of roughened metal cup of 
slightly greater size and typically made of titanium is impacted into 
the acetabulum. The inner portion of the cup may then have a 
surface inserted into it that is comprised of either high density 
plastic, ceramic, or metallic cobalt-chrome alloy on which a new 
femoral head will articulate. The upper femur is then prepared with a 
series of instruments. A metallic stem most commonly made of 
titanium and of appropriate size is inserted into the upper femur. The 
stem typically has a bare neck on which is placed a head of one of 
varying sizes that is comprised of either ceramic or of a cobalt-
chrome alloy. 
                                                 
13 For a complete discussion of the various surgical approaches to 
the hip, see Stanley Hoppenfield, Piet Deboer, Surgical Exposures in 
Orthopaedics: The Anatomic Approach, 302-357 J.B. Lippincott 
Company, 1984. 
6https://open.mitchellhamline.edu/cybaris/vol9/iss2/4
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B. Current Technology 
 In 2016, the orthopaedic device industry generated revenue 
of $48.1 billion, and a nearly $7 billion was specifically related to 
implant hip arthroplasty components.14 Hip implant technology 
revenue therefore accounts for approximately fifteen percent of the 
total implant device market. Other sectors of the orthopedic device 
implant market would include prosthetic joint implants such as total 
knees, shoulders, and elbows; fracture fixation hardware such as 
various plates, screws, and rods; and spinal stabilization hardware 
such as pedicle screws, rods and fusion plate systems. There are 
several reasons hip implants comprise this percentage of the market 
and for similar reasons it is also expected that the hip implant market 
will continue to grow.   
                                                 
14 Carolyn LaWell, Orthopaedic Industry Revenue Reaches $48.1 
Billion, Orthoworld, Apr. 21, 2017, 
https://www.orthoworld.com/index.php/publications/orthoknow_con
tent/orthopaedic-industry-revenue-reached-48-1-billion-worldwide-
in-20. 
7Published by Mitchell Hamline Open Access, 2018
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 First, it is estimated that the demand for total hip replacement 
will continue to grow as a result of the general aging of the 
population and the demand of the population to maintain an active 
lifestyle. Epidemiological data has been difficult to harvest regarding 
THR from a national perspective, since there is no mandatory total 
joint arthroplasty registry as currently exists in other countries like 
the United Kingdom. There is, however, an ongoing initiative for 
developing a national Joint Registry Program. At this time, it is 
currently voluntary. The program began in 2010 as a not-for-profit 
501c(3) organization involving fifteen voluntarily participating 
hospitals.15 Only in 2016 was the registry recognized as such by the 
American Association of Hip and Knee Surgeons (AAHKS), and as 
of 2017 there were just over one million joint replacements being 
tracked in the registry.16 This presently accounts for one of seven 
million calculated total hip and knee components currently 
implanted in patients in the United States.17 
 Second, hip replacement surgery is increasingly being 
performed in younger individuals who wish to maintain an active 
and demanding lifestyle. When originally conceived and designed, 
THR was primarily to be an operation for older individuals. 
Currently, it is not uncommon for patients in their forties to undergo 
joint replacement surgery. 
                                                 
15 See AMERICAN JOINT REPLACEMENT REGISTRY, 
http://www.ajrr.net/about-us/about-our-organization/about-history-
milestones (last visited on Apr. 19, 2018). 
16 Id. 
17 See Hilal Maradit Kremers et al, Prevalence of Total Hip and 
Knee Replacement in the United States, 97, J Bone Joint Surg, Sept. 
2, 2015, at 1386. 
8https://open.mitchellhamline.edu/cybaris/vol9/iss2/4
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 Third, more complex revision hip surgery will be required 
because individuals who are having their hips replaced are living 
longer, and their lifespan is exceeding that of their replaced 
prosthetic joints. This necessitates even more complex and 
expensive revision or repeat joint replacement surgery. Again, the 
actual epidemiological data are difficult to estimate, but when 
considering the increases in primary (first) total hip replacements 
and revision (re-do) total hip replacements, there is an expected 
growth of 174 percent for primary total hip replacements and 137 
percent for revision total hip replacements by the year 2030.18 
 Fourth, in an effort to subvert the inevitable mechanical wear 
properties of prosthetic hip components, the biomedical device 
industry is attempting to develop strategies to decrease the wear of 
implanted devices and to increase the lifespan of these same devices. 
This has resulted in implant manufacturers seeking new technologies 
to achieve this goal. These efforts have followed several pathways.  
 Manufacturers have sought to improve the manner in which 
these various devices are fixed to the bone, and two basic 
mechanisms exist to accomplish this. Either the components are 
“cemented” into place utilizing a biomedical polymer known as 
polymethylmethacrylate, or they are placed in “press-fit” fashion by 
machining the femur or the acetabulum (or both) to a size slightly 
smaller than the components that are implanted. The implanted 
components are then pounded into place and initially held by the 
mechanical interface between the bone and the metallic parts. When 
“press-fit” fixation is utilized, the components are designed in such a 
way that the bone will actually grow to the implanted devices over 
an approximately six-week period. 
 Device manufacturers have sought to preserve the native 
bone stock in patients by decreasing the size of implanted 
components. This has resulted in a decrease in the amount of bone 
removed at the index operation. The rationale is that by minimizing 
the initial removal of bone at the index operation, more bone will be 
preserved for future operations, should they become necessary. 
                                                 
18 A. Patel, G. Pavlou, R.E. Mujica-Mota, A.D. Toms, The 
Epidemiology of Revision Total Knee and Hip Arthroplasty in 
England and Wales, 97-B, Bone Joint J, July 29, 2015 at 1076. 
9Published by Mitchell Hamline Open Access, 2018
                    CYBARIS®, AN INTELLECTUAL PROPERTY LAW REVIEW                              314 
 
 Finally, and most importantly for this discussion, implant 
manufacturers have sought means by which to modify the bearing 
surfaces of the parts that articulate and rub against each other in the 
artificial hip joint. Bearing surfaces currently involve one of several 
permutations: (1) a metal ball that articulates on a plastic liner within 
the socket of the artificial hip joins: (2) a metal ball that articulates 
on a metal socket within the socket of the artificial hip joint; (3) a 
ceramic ball that articulates on a plastic bearing within the socket of 
the artificial hip joint; and (4), a ceramic ball that articulates on a 
ceramic bearing within the artificial hip joint. While some of these 
various combinations are “new,” the history of how arthroplasty 
developed is relevant to understanding the issue. 
 C. Economic Impact 
 It is anticipated that there will be a substantial increase in 
both primary and revision THR as projected from the year 2005 to 
the year 2030.19 As can be expected, this will result in a substantial 
economic burden on the United States health care system. 
Furthermore, from the current year to 2030, it is reasonable to 
anticipate that there will be technological advances necessitating 
intellectual property protection—most likely by way of the USPTO--
as well as medical device regulation and approval by the FDA. 
                                                 
19 S. Kurtz, K. Ong, E. Lau, F. Mowat, and M Halpern. Projections 
of Primary and Revision Hip and Knee Arthroplasty in the United 
States from 2005 to 2030, 89(4), J Bone Joint Surg Am, April 1, 
2007 at 780.  Primary THR is expected to increase by 174 percent; 
revision THR is expected to increase by 137 percent. 
10https://open.mitchellhamline.edu/cybaris/vol9/iss2/4
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 The cost for the surgical event alone of total hip arthroplasty 
is currently measured at approximately $30,000. For revision hip 
arthroplasty it is $38,000 per event.20 “The enormous growth in hip 
arthroplasty may be justified by the fact that, despite its high cost, 
total hip replacement (THR) is an extremely cost-effective treatment 
intervention.21 As previously stated, THR is not simply a procedure 
performed on the elderly. “The demand for THA in patients younger 
than 65 years also is increasing, further increasing the disease burden 
of revision THA.”22 Even more concerning is that all projections are, 
at best, estimates, and are frequently underestimated in that the 
“actual number of revision THAs in 2006 exceeded the projected 
number of revision THA by >10,000 cases.”23   
 These data all point to a significant growth in this area of the 
healthcare market. They also likely indicate an increase in the 
development of new technologies produced by manufacturers and 
inventors who will have a vested interest in protecting their 
intellectual property investments. 
III. Utility and Novelty 
 A. History 
 In order to qualify for a patent, there has been a longstanding 
requirement that a patent applicant must demonstrate that an 
invention fulfills the requirements of novelty and utility.24 
                                                 
20 See R. Bitton, The Economic Burden of Osteoarthritis, 15(8)  
Amer Journ Man Care. 2009, at S233-235; see also J. N. Katz JN. 
Total joint replacement in osteoarthritis 20(1), Best Pract Res Clin 
Reheumatol, 2006 at 145. 
21 Id. 
22 Nho SJ et al, The Burden of Hip Osteoarthritis in the United 
States: Epidemiologic and Economic Considerations. 21(Suppl) 
JAAOS: 2013 at S1. 
23 See id.; see also S. Kurtz, supra note 19. 
24 Supra notes 1 and 2. 
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 The consideration of both novelty and utility as patent 
requirements necessitates a historical review of these elements. As 
the development of American jurisprudence is founded in the 
traditions of English common law, so it is true that the authors of the 
Constitution framed the concept of early United States patent law on 
historical English precedents.25 The earliest English concept of 
patents was based on ad hoc, discretionary royal grants. These grants 
from the Crown were initially focused on the development and the 
furtherance of new aspects and avenues of trade and economic 
growth. The protection of the rights of inventors was not considered 
when the Crown was granting patents.26 Early patents were not seen 
as a “right” to intellectual property protection of an inventor. 
“Petitions contained recitals of utility[,]”27 but it was not until the 
early seventeenth century that “the new common law thinking about 
monopolies began to stress novelty as an essential element of lawful 
patents . . . .”28 As British colonies were established in North 
America, the patent system in the Colonies mirrored the system in 
England. However, there was no unified patent system spanning the 
early nation. Even after the Revolutionary War, the individual states 
retained the rights to protect and regulate intellectual property, as 
there were no provisions written into the Articles of Confederations. 
It was not until 1789 that the “U.S. Constitution changed this 
situation and laid the foundation for national patent and copyright 
regimes.”29 
                                                 
25  Oren Bracha, Owning Ideas; The Intellectual Origins of American 
Intellectual Property, 1790-1909 at 12-19 (Cambridge University 
Press, 2016). 
26 Id. 
27 Id. at 17. 
28 Id. at 18. 
29 Id. at 47. 
12https://open.mitchellhamline.edu/cybaris/vol9/iss2/4
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 The authors of the Constitution specifically enshrined what 
was to become known as the “intellectual property clause”30 in 
Article I, Section 8, clause 8 whereby it was established that “The 
Congress shall have Power . . . [t]o promote the Progress of Science 
and useful Arts, by securing for limited Times to Authors and 
Inventors the exclusive Right to their respective Writings and 
Discoveries . . . .”31 Utilizing its newly granted authority, Congress 
passed the Patent Act of 1790.32 The Patent Act provided for patents 
of “any useful art, manufacture, engine, machine, or device, or any 
improvement therein not before known or used.”33   
 The Patent Act of 1790 was later replaced by the 1836 Patent 
Act which again stressed the requirements of utility and novelty; 
furthermore, the 1836 Act established the “Patent Office [as] a 
distinct and separate bureau in the Department of State . . . .”34 This 
and other types of intellectual property have been entrusted to the 
United States Patent Trademark Office (USPTO).35 The regulation 
of these devices once invented, however, is currently under the 
auspices of the Food and Drug Administration.36 There is, at present,  
a substantial disconnect between the legal framework under which 
these the intellectual property of medical devices is protected by 
patent law and subsequently approved for use in the public domain. 
                                                 
30 Id. 
31 U. S. Const. Art 1, § 8, cl. 8. 
32  SHELDON W. HALPERN, KENNETH L. PORT, SEAN B. 
SEYMORE, FUNDAMENTALS OF UNITED STATES 
INTELLECTUAL PROPERTY LAW, at 155-158, (Wolters Kluwer 
5 ed. 2015); see also Act of Apr. 10, 1790, ch. 7, I Stat. 100. 
33 Id. 
34 Id. at 157. 
35  35 U.S.C. § 2 (2017). 
36  21 U.S.C. § 301 (2017). 
13Published by Mitchell Hamline Open Access, 2018
                    CYBARIS®, AN INTELLECTUAL PROPERTY LAW REVIEW                              318 
 
 In order to protect the intellectual property aspects of the 
growing orthopaedic market, inventors have been relying on the 
patent process to protect their economic interests.37 Countless 
patents have been issued for orthopaedic implant designs, surgical 
instruments used to insert the devices, and even for protective 
clothing used while performing the procedure.38 Patents were sought 
by Charnley and by George McKee for their pioneering implants in 
the latter half of the twentieth century.39 More recently, a Patent 
Number U.S. 5904720 A was issued to Johnson & Johnson 
Professional, Inc., the parent company of DePuy Orthopaedics, for a 
hip joint prosthesis with a metal-on-metal articulation between the 
prosthetic femoral head and the acetabular prosthetic component.40 
These are the types of components that were subsequently released 
after regulatory approval as substantial equivalents for implantation 
into patients worldwide.    
 Given recent events in the realm of medical devices, perhaps 
it is time to re-evaluate how the intellectual property of these devices 
is protected. 
                                                 
37 Supra note 1. 
38 Supra note 6; U. S. Patent No. 3667456 A (filed Nov 19, 1970); 
U. S. Patent No. 3625206 A (filed Nov 3, 1969). 
39 See U. S. Patent No. 4327449 A (filed Jun 26, 1980); see also U. 
S. Patent No. 5904720 A (filed Aug 12, 1997). 
40 U. S. Patent No. U.S. 5904720 A (filed May 18, 1999). 
14https://open.mitchellhamline.edu/cybaris/vol9/iss2/4
                    CYBARIS®, AN INTELLECTUAL PROPERTY LAW REVIEW                              319 
 
B. Current Statutory Structure of Novelty and Utility 
  1. Novelty 
 The current statutory language governing patent law has most 
recently been updated in the Leahy-Smith America Invents Act of 
2011.41 It requires that devices be, among other things, novel42 and 
useful.43 
 Specifically, the requirement for novelty indicates that a 
patent may be granted to an individual unless the invention was 
previously patented or described in a printed publication or was 
available to the public commercially as set forth in the elements of 
35 U.S.C § 102. The courts have upheld that “[d]esign patent 
infringement occurs only when the accused design is ‘substantially 
the same’ as the claimed design.”44   
                                                 
41 P.L. 112-29, Sept 16, 2011, 125 STAT. 284. 
42 35 U.S. C. § 102 (2011). 
43 35 U. S. C. § 101 (2006). 
44 Sun Hill Industries, Inc. v. Easter Unlimited, Inc 48F. 3d 1193, 
1196 (U.S.C.A, Fed Cir, 1995). 
15Published by Mitchell Hamline Open Access, 2018
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 When inventions are not new, they are said to be “anticipated 
by prior art.”45 In order for prior art to defeat an alleged new 
invention’s claim of novelty, three conditions must be fulfilled: (1) 
the prior art’s invention date must pre-date the new invention 
development; (2) the prior art must be strictly identified; and (3) the 
prior art’s description must be “enabling”—that is, it must be 
sufficiently described such that a person having ordinary skill in the 
realm of the art described would be “enabled” to re-create the 
invention.46 As will be discussed later, one of the critical aspects of 
the recent production and sale of hip arthroplasty implants has been 
a reliance on the FDA’s 510(k) process for approval. This process 
provides for the approval of implants that have been previously 
invented and are “substantially equivalent” to formerly approved 
medical devices.47 If devices are determined to be “substantially 
equivalent,” it raises the issue of how such devices would fulfill the 
definition of novelty. 
 Novelty has been established from the earliest days of patent 
legislation vis a vis the Patent Act of 1790, as an essential 
requirement for an invention to receive a patent. Yet, the concept of 
substantial equivalence for FDA regulatory purposes would seem to 
contradict the element of novelty. 
  2. Utility 
 Analyzing the requirement for utility would appear to be 
intuitive.  Implantable hip devices would be seen to be useful if they 
are capable of functioning as a prosthetic hip for an extended period 
of time. 
                                                 
45 S. Halpern et al, supra 32 at 167. 
46 S. Halpern et al, supra 32 at 167-69. 
47 See 21 U.S.C. 360c (2017), Notes of Decisions “Premarket 
approval.” 
16https://open.mitchellhamline.edu/cybaris/vol9/iss2/4
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   When considering the requirement for utility as set forth in 
35 U.S.C. § 101, courts have previously stated that the utility 
threshold is not high and “an invention is ‘useful’ under section 101 
if it is capable of providing some identifiable benefit.”48 In Brenner 
v. Manson, the Supreme Court acknowledged that the concept of 
utility has maintained a central place in all of our patent legislation 
beginning with the first patent law in 1790 . . . .”49 However, the 
Court also acknowledged that “[a]s is so often the case, however, a 
simple, everyday word can be pregnant with ambiguity when applied 
to the facts of life.”50 Such is the essence of the debate regarding 
“utility” when it comes to implantable, medical devices—
specifically in the realm of prosthetic hips.   
                                                 
48 Juicy Whip, Inc., v. Orange Bang, Inc, 185 F. 3d 13664, 1366, 
(USCA, Fed. Cir, 1999). 
49 Brenner v. Manson 383 U.S. 519, 529 (1965).   
50 Id. 
17Published by Mitchell Hamline Open Access, 2018
                    CYBARIS®, AN INTELLECTUAL PROPERTY LAW REVIEW                              322 
 
 The Brenner case involved debate about the regarding the 
utility of a chemical process. There is no doubt that when the 
Constitutional authors created the “intellectual property clause,” 
such chemical processes did not exist.  One must remember that the 
tradition regarding patents had strong ties to the concept of 
increasing aspects of trade.51 Certainly “machines” or “devices” 
existed in Colonial America, but there is little doubt that the 
concepts of such machines and devices had not extended to include 
implantable prosthetic joints comprised of metal, plastic, and 
ceramic. As biomedical technology progresses, the courts have faced 
increasing challenges in determining what patented or patentable 
inventions fulfill the statutory requirement of being useful. This is 
readily demonstrated as the courts attempt to address the intellectual 
property questions involving, for example, the technologies used for 
testing, delineating, and manipulating human genetic sequences. 
“Patent protection strikes a delicate balance between creating 
‘incentives that lead to creation, invention, and discovery’ and 
‘imped[ing] the flow of information that might permit, indeed spur, 
invention’”52  
                                                 
51 O. Bracha, supra note 25. 
52 Ass’n for Molecular Pathology v. Myriad Genetics, Inc. 569 U. S. 
576, 576 (2013) (citing Mayo Collaborative Services v. Prometheus 
Laboratories, Inc. 566 U. S. 66 (2012)). 
18https://open.mitchellhamline.edu/cybaris/vol9/iss2/4
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 Modern implantable medical devices can be said to be useful 
if they are safe, if they achieve their desired clinical result, and if 
that clinical result is at least as successful as or preferably more 
successful than currently existing clinical technology. Yet here 
again, the simple word “safe” is an example of a word “pregnant 
with ambiguity when applied to the facts of everyday life.”53 Justice 
Story stated in Lowell v. Lewis that “[a]ll that the law requires, is that 
the invention should not be frivolous or injurious to the well-being, 
good policy, or sound morals of society.”54   
 In the realm of orthopaedic prosthetic hip implants, these 
determinations can be difficult to establish at the time of patent 
application.  Typically patents are applied for and granted after their 
invention in order to protect the intellectual property of the inventor. 
However, such patents are granted for devices prior to their 
evaluation for safety and efficacy by the Food and Drug 
Administration. In the case of prosthetic total joint implants, once 
the FDA grants approval for their use, they are released to market 
and are available for surgical implantation.  Inventors, whether they 
are clinical physicians or implant manufacturing companies, have an 
interest in obtaining patents to protect their intellectual property and 
then delivering their products to market as quickly as possible in 
order to generate revenue to recover their costs for research and 
development and to please their shareholders.   
                                                 
53 Brenner, 383 U. S. at 529. 
54 Lowell v. Lewis 1 Mason 182 Circuit Court, D. Mass 15 F. Cas 
1018, 1019 (1817). 
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 In reality, the true evaluation for safety and efficacy begins 
once these types of medical devices reach the medical marketplace.  
Patients receiving prosthetic hip implants are counselled by prudent 
orthopaedic surgeons that their implant is a mechanical device and, 
like all mechanical devices, can wear out and need to be redone at 
some point in the future.  A total hip patient in the United States 
could generally expect a ninety percent chance that their total hip 
would last between ten and fifteen years.55 
 When examining the recent events surrounding certain hip 
implants, it becomes obvious that certain devices were granted 
patents that were of questionable usefulness because their safety was 
suspect due to early clinical failures and due to a need for early 
revision surgery. Furthermore, when examining the process by 
which these types of devices were cleared by the FDA, their novelty 
may also be considered suspect. 
IV. FDA Origins and Authority Approval Process 
 A. Origins and Authority 
 It is important to understand the origins of Food and Drug 
Administration when considering the evolution of its relationship 
with the USPTO. Additionally, this relationship has historically 
resulted in the regulation of medical devices. 
                                                 
55 Jeffrey N. Katz, MD, MSc et al, Failures of Total Hip 
Replacement: A Population-Based Perspective, ORTHO J HARV 
MED SCHOOL, Vol 9, Manuscripts, 103. 
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 The United States Patent and Trade Office and the Food and 
Drug Administration share a common heritage dating back to 1848. 
It was around this time that chemist Lewis Caleb Beck was assigned 
to the Patent Office to perform chemical testing on agricultural 
products, and this function was subsequently assumed under the 
Division of Chemistry and later the Bureau of Chemistry of the 
United States Department of Agriculture in 1862.56 The passage of 
the Federal Food and Drugs Act, in 1906, “added regulatory 
functions to the agency’s scientific mission[,]” and was the 
beginning of the development of the modern Food and Drug 
Administration which was established by the Federal Food, Drug, 
and Cosmetic Act of 1938.57 The FDA currently operates under the 
direction of the Department of Health and Human Services.58 
 As part of its function, the Food and Drug Administration has 
been granted authority to regulate medical devices under the Federal 
Food, Drug, and Cosmetic Act.59  This authority is based in the 
“constitutional power of Congress to regulate interstate commerce” 
and to protect the public health “to the end that public health and 
safety might be advanced.60 Prior to 1976, both pharmaceutical 
agents and medical devices were regulated together in the same 
fashion under the auspices of the FDA.   
 B. The Medical Device Amendments 
                                                 
56   U.S. FOOD & DRUG ADMINISISTRATION, 
https://www.fda.gov/AboutFDA/WhatWeDo/History/ (last visited 
on Apr. 19, 2018). 
57   Vincent A. Kleinfeld, Legislative History of the Federal Food, 
Drug, and Cosmetic Act, 50 Food & Drug L.J. 65, 65-100, 1995. 
58   U.S. FOOD & DRUG ADMINISISTRATION, 
https://www.fda.gov/AboutFDA/WhatWeDo/History/Origin/ucm124
403.htm (last visited on Apr. 19, 2018). 
59 21 U.S.C. §301, Chapter 9, Subchapter V—Drugs and Devices. 
60 21 U.S.C. §301, Note 1 (2017). 
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 In 1976, the Medical Device Amendments (MDA) were 
adopted to specifically address issues related to the safety, 
regulation, and marketing of medical devices.61 In order to address 
issues specifically related to medical devices, the MDA subdivided 
various medical devices into three classes. The types and 
requirements of Class I, Class II, and Class III devices are set forth 
in 21 U.S.C. § 360c. Surgically implanted hip arthroplasty 
components are Class III devices as outlined in 21 U.S.C. § 360(c) 
and are subject to the highest level of FDA regulation.   
 Since its inception as a one-person department in the 
USPTO, the FDA has operated under various federal departments to 
assess the safety of medical devices available to the public. Later, 
the FDA was granted regulatory authority with ability to classify 
medical devices and to require manufacturers to demonstrate 
medical device safety prior to public marketing of such devices.   
C. Avenues of Approval for Medical Devices 
 Since the MDA of 1976, the FDA has allowed medical 
device approval by one of two pathways: (1) the premarket approval 
process (PMA); and (2) the 510(k) approval process. The first is a 
prospective analysis. The second is a retrospective analysis based on 
“substantial equivalence.” 
                                                 
61 See Pub. L. 94-295 May 28, 1976; see also 21 U.S.C. §360 (2017). 
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 In general, devices that do not fall under Class I or Class II, 
that are “purported or represented to be for a use in supporting or 
sustaining human life,” and that “present a potential unreasonable 
risk of illness or injury” are “ subject . . . to premarket approval to 
provide reasonable assurance of [] safety and effectiveness.”62 Class 
III devices require Premarket Approval whereby a device’s safety is 
assessed prior to its release to the medical community for use and 
distribution to the public.63 In addition, new medical devices that 
seek approval through PMA “require[] an investigational new device 
(IND) application and a small safety trial . . . . The trials are typically 
randomized, can cost millions of dollars, and can require several 
years to complete.”64 However, an exception is provided for under 
Section 360(c) when a device had been approved prior to the MDA, 
and the device is “grandfathered” by a provision allowing pre-1976 
devices to remain on the market.65 
                                                 
62 See 21 U.S.C., § 360(c) (2017): see also 21 U.S.C. 360(e) (2017). 
63 21 USC 360c (2017). 
64 Travis Maak, James Wylie, Medical Device Regulation: A 
Comparison of the United States and the European Union, 24(3), 
JAAOS, May, 2016. 
65 Id. 
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 In order to “prevent manufacturers of grandfather devices 
from monopolizing the market while new devices clear PMA,” the 
FDA allows devices to be approved for use by a separate process 
known as the 510(k) process.66 The 510(k) process does not require 
clinical testing and reporting of results to the FDA prior to medical 
device approval for use. Instead, under 510(k) approval, a device is 
determined to be “substantially equivalent” to a device that had been 
approved prior to 1976, and consequently such a device may be 
approved for use without undergoing the more rigorous PMA 
process. 67   
 The ability to obtain 510(k) approval has provided a means 
by which inventors and developers of hip arthroplasty components 
may introduce new devices in order to gain access to the 48.1 billion 
dollar orthopaedic implant device market without having to invest in 
the more lengthy and expensive clinical trial process prior to FDA 
approval for use.   
 The current patent process provides the device developers a 
means by which they may protect their intellectual property in this 
potentially lucrative aspect of the medical device market.   
 As noted above, the 510(k) approval process requires 
significantly less time than the PMA process. Consequently, 
inventors will have their intellectual property investment protected 
for a longer time because patent protection will not have been 
consumed while waiting for market approval by the FDA. The Court 
noted in Medtronic v. Lohr that the PMA review and the 510(k) 
notification demonstrate significant time requirements with “1,200 
hours necessary to complete a PMA review, [while] the § 510(k) 
review is completed in an average of only 20 hours.” 68 
                                                 
66 See supra note 47 
67 Id. 
68 Medtronic, Inc. v. Lohr, 518 U.S. 470, 478 (1996). 
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 The 510(k) approval process is substantially less expensive to 
manufacturers. “The mean cost from concept to approval reported in 
an industry survey was $31 million for devices approved through the 
510(k) process and $94 million for devices approved through PMA . 
. . .”69   
 In an effort to prevent monopolization and the attendant 
increase in healthcare cost, Congress passed the Hatch-Waxman Act 
in 1984.70 This effort produced a means by which pharmaceutical 
manufacturers of generic drugs could “seek approval through 
establishing bioequivalence to a previously approved pioneer 
drug.”71 The Hatch-Waxman Act, however, did not extended an 
abbreviated approval process to medical devices.72 The Act, 
however, did provide a possibility for patent extension for both new 
drugs and for new medical devices in order to offset the time of 
patent protection lost while FDA approval is sought, and this has 
further been verified by the Supreme Court.73 
                                                 
69 See T. Maak, supra note 65; see also J. Makeower, A. Meer, L. 
Denend, FDA impact on U.S. medical technology innovation: A 
survey of over 200 medical technology companies.  Washington, DC, 
Advanced Medical Technology Association, 2010. 
HTTP://advamed.org/res.download/30. 
70 Pub. L. No. 98-417, 98 Stat. 1585 (1984) (codified as amended in 
sections of 21 U.S.C. and 35 U.S.C.). 
71 Brian P. Wallenfelt, “Hatch-Waxman and Medical Devices,” 
WILLIAM MITCHELL L. REV. 1407, 1415 (2014). 
72 Id.at 1418. 
73 See Id. at 1419; see also Eli Lilly v. Medtronic, Inc. 496 U.S. 661 
(1990). 
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 From a public policy perspective, there are two main 
considerations. First is the interest of the federal government via the 
FDA in insuring the public release of medical devices with the safest 
and most efficacious clinical profile to the public.  Medical devices 
that are safe and efficacious—that is, devices that provide utility—
will provide for the maintenance and improvement of the public’s 
health at the least cost to government and to the commercial 
insurance industry. Devices that are safe and efficacious will likely 
require the least long term clinical surveillance because their long 
term safety will have been established. Furthermore, such devices 
will require the least amount of ongoing medical corrective 
intervention because the predictability of their long term clinical 
profile will have demonstrated the least need for future intervention. 
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 Second, the policy of the federal government is to encourage 
competition to minimize monopolization of the market. 
Monopolization is likely to result in domination of the medical 
device market by a few larger manufacturers that have the resources 
to pursue the more expensive and lengthy PMA process.74 In passing 
the Hatch-Waxman Act, the federal government’s desire to 
encourage competition and decrease cost was codified by facilitating 
the development of the generic drug market. This particular desire 
was not, through the Act, extended to the medical device market, 
although patent extension was extended to medical devices.75  As 
noted in Wallenfelt’s article, there is a significant cost differential 
regarding the development, testing, and manufacture of 
pharmaceutical agents as compared to medical devices. With 
pharmacological agents the majority of the expense is related to the 
research, development, and testing of the agents.  Once approval is 
granted, the actual manufacturing cost represents only a small 
portion of a company’s expense. In contradistinction, medical device 
manufactures of complex, Class III medical devices, have a 
significantly larger cost burden with manufacturing the devices. 
While development and testing—be it via the PMA process or the 
510(k) process—can require significant financial investment, 
ongoing manufacturing costs remain a substantial burden to the 
manufacturer. This is true whether the manufacturer is the initial 
developer or is a subsequent generic manufacturer. Consequently, 
the generic manufacture does not realize as substantial a cost 
reduction in assuming the production of previously developed and 
approved devices.76 
                                                 
74 Wallenfelt, supra note 71 at 1422. 
75 Id. at 1422. 
76 Id. 
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 The introduction of the PMA the 510(k) processes was an 
attempt to balance the FDA’s insurance of utilitarian medical 
devices via established safe and effective clinical profile against the 
government’s and the public’s interest in attempting to minimize the 
cost burden to federal and commercial payers and, eventually, to the 
public. As subsequent discussion will demonstrate, the outcome of 
the steps taken can likely be viewed as having the opposite, 
unintended effects. 
D. The Intellectual Property Protection Problem With 
510(k) Approval 
 Two significant issues arise with the patent requirements for 
novelty and usefulness as applied to medical devices.   
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 As noted above, the first problem inventors face is that 
temporally, FDA approval is sought after patent application.  This 
creates two problems for inventors and for the USPTO. The first 
problem is that inventors creating medical devices still are required 
to obtain FDA approval before their inventions can be released in the 
marketplace. As previously mentioned, either the PMA process or 
the 510(k) process are the regulatory avenues that would potentially 
be utilized for medical devices, and there is no other streamlined 
mechanism for devices as there is for generic drugs provided by the 
Hatch-Waxman Act.77 When assessing hip implant devices, the 
PMA process is particularly onerous because PMA requires clinical 
trials, and clinical trials for hip implants could go on for several 
years prior to determining the true safety and efficacy of using 
certain components. Early implant failures detectable in a short 
survey would not necessarily be related to failure of the function of 
the prosthetic implants themselves.  Rather, early failures would be 
more likely related to surgical morbidity and mortality—including 
events such as periprosthetic joint infection, thromboembolic events 
such as deep venous thrombosis and pulmonary embolism, and 
postoperative patient death due to comorbid conditions such as 
coronary and carotid arterial disease. Hip replacement survivability 
of the implants themselves is typically assessed in short, medium, 
and long term implant survival which roughly could be divided into 
two, five, and ten or more years. Occurrences such as excessive 
bearing wear, host response osteolysis, galvanic trunionosis, and 
implant loosening from bony fixation may not manifest during the 
initial year or two of early clinical trial.78 All the while during such 
clinical trials the clock is ticking as to the lifetime of a patent that 
protects a developer’s investment. Patent terms typically are granted 
for periods of twenty years from the time of patent application.79 If 
PMA is employed and long term studies are utilized, more than half 
of a patent’s life could be consumed before any return on investment 
is realized by inventors and developers. The Supreme Court noted in 
Eli Lilly & Co. v. Medtronic that “if the discovery relates to a 
product that cannot be marketed without substantial testing . . . the 
‘clock’ on his patent term will be running even though he is not yet 
able to derive any profit from the invention.”80 Even though the 
Hatch-Waxman Act made provision for extending a patent for 
medical devices in compensation for time lost awaiting regulatory 
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approval, the combined period for such extension when combining 
time awaiting regulatory approval and remaining patent term shall 
not exceed fourteen years.81 
 The second problem is that if the USPTO grants a patent 
under these circumstances, it does so without truly determining 
whether a device is useful, because the FDA has not yet deemed it to 
be safe.   
 The Patent Office and certain jurisdictions have held that a 
medical invention, to be patentable, must be shown safe and actually 
effective by the performance of clinical tests on humans.  A second 
theory, which is now  firmly rooted in the Court of Customs and 
Patent Appeals (CCPA), is that a showing of safety . . . is not 
necessary to satisfy the statutory requirement . .  . .82 
                                                 
77 See Robert A. Armitage, The Hatch-Watchman [sic] Act: A Path 
forward for Making It More Modern WILLIAM MITCHELL L. 
REV. 1200-1259 (2014) for discussion of this issue. 
78  Osteolysis is a condition whereby (whereby a patient develops 
large cysts in the bone around an implant because of response to 
microscopic wear particles); galvanic trunionosis is a condition 
whereby (whereby electromagnetic currents between metal 
components of differing types cause metallic corrosion) 
79 35 U.S.C 154(a)(2) 2017 
80   Eli Lilly and Co. v. Medtronic, Inc. 596 U.S. 661, 669-70 (1990) 
81   35 U.S.C. § 156(c)(3).  
82 C. Leon Kim, The Utility Requirement for Patenting Therapeutic 
Inventions, 24 BUFF. L. REV. 595, 612 (1975) 
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 The Supreme Court has previously ruled that “any decision 
by the FDA on the safety and effectiveness of a new drug is 
irrelevant to the issue of patentability.83 Pharmaceutical evaluation, 
however, evolves differently than evaluation for medical devices in 
that the majority of drugs do not have cumulative effects, so their 
safety and efficacy can be more readily evaluated in shorter term 
clinical trials than the long term surveillance need to assess medical 
device performance. Other drugs, such as Adriamycin, have dose-
dependent effects that are cumulative and require longer terms of 
assessment similar to the evaluation of medical devices.84 
Furthermore, these types of judicial decisions were made primarily 
related to the use of pharmaceutical agents. They were made at a 
time before the widespread implantation of prosthetic joint implants 
in large segments of the population. The Supreme Court’s opinion in 
Brenner was decided in 1965, at a time when total hip replacement 
was in its earliest stages of development. In 2010, 310,000 total hip 
replacement procedures were performed, and it is estimated that 
there are approximately 2.5 million implanted total hip replacements 
in the United States.85 
 The second problematic consideration is how the 510(k) 
approval process relates to the novelty requirement of patents 
embodied in 18 U.S.C. § 102. The 510(k) approval process is 
employed to bypass the FDA’s PMA requirement. When applying 
for 510(k) approval, a device is claimed to be “substantially 
equivalent” to a device previously approved by the FDA. 
                                                 
83 Id. at 596; see Brenner v. Manson, 383 U.S. 519 (1966); see also 
Application of Hartop 311 F. 2d 249, 257 (C.C.P.A 1962). 
84  Adriamycin is a chemotherapy agent that may be used for 
treatment of breast cancer. 
85 Maradit Kremers, et al, Prevalence of Total Hip and Knee 
Replacement in the United States, J BONE JOINT SURG AM, 2015 
Sep 2, 97(17), 1386-97. 
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 This generates two issues for consideration.  First, if a device 
is substantially equivalent, then does it truly fulfill the novelty 
requirement of § 102?  Perhaps one needs to the look to third 
statutory requirement introduced by the Patent Act of 1952 to 
establish patentability—the requirement of non-obviousness.86  The 
non-obvious subject matter requirement specifically states that “if 
the differences between the claimed invention and the prior art are 
such that the claimed invention as a whole would have been obvious 
before the effective filing date of the claimed invention to a person 
having ordinary skill in the art to which the claimed inventions 
pertains.”87 The requirements of utility, set forth in § 101, and 
novelty, set forth in § 102, have been longstanding elements of 
patentability dating back to the passage of the Patent Act of 1790. 
However, the concept of novelty was further delineated with the 
addition of the requirement of non-obvious subject matter. Though 
non-obviousness was codified in 1952, there is a long judicial 
history of the application of the Hotchkiss test stemming from the 
1851 Supreme Court decision in Hotchkiss v. Greenwood, 11 How. 
248, 13 L. Ed. 683.88 
                                                 
86 The current variation is found in 35 U.S.C. § 103 (2011). 
87 35 U.S. C. § 103 (2011). 
88 See Graham v. John Deere Co. of Kansas City, 383 U.S. 1, 684, 
687-695 (1966) for J. Clark’s discussion of the evolution of this 
judicial precedent and its eventual embodiment in the Patent Act of 
1952. 
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 The Hotchkiss test informally established in 1851 states that 
“unless more ingenuity and skill . . . were required . . . than were 
possessed by an ordinary mechanic acquainted with the business, 
there was an absence of that skill and ingenuity which constitute 
essential elements of every invention.”89 The non-obviousness 
requirement, then, further delineates the novelty requirement such 
that “[a]n invention which has been made, and which is new in the 
sense that the same thing has not been made before, may still not be 
patentable . . . .”90 
                                                 
89 See Id. at 684, 690; see also Hotchkiss v. Greenwood, 11 How. 
248, 267, 13 L. Ed. 683. 
90 Graham, at 692. 
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 The result of the current scheme is that implant 
manufacturers are currently designing and seeking patents for new 
variations of total hip implants claiming they are useful, fulfilling the 
§ 101 requirement, novel, fulfilling the § 102 requirement, and non-
obvious, fulfilling the § 103 requirement.  The manufacturers are 
then taking their patented designs to the FDA and pursuing 510(k) 
approval based on arguments of substantial equivalence. They are 
claiming that the newly designed or modified implants are similar 
enough to those previously approved and consequently should be 
granted FDA 510(k) approval. This is all done with the intention of 
protecting the intellectual property investment in time and in capital 
with the limited monopoly of a patent, but avoiding the time, 
expense, and prolonged consumption of patent protection by the 
onerous PMA approval process.   
 Historically, substantially equivalent devices have been 
approved by the FDA based on devices that were previously 
approved.  However, there are instances where medical devices have 
been subsequently voluntarily withdrawn or voluntarily recalled by 
manufacturers because of poor clinical performance of the devices or 
because of safety concerns.  The quintessential example of this is the 
recent activity surrounding the ASR metal-on-metal hip 
manufactured by DePuy.91  The ASR hip was approved for sale in 
the United States by the FDA in July, 2008 based on a 510(k) 
clearance application. This application was based, among others, on 
U. S. Patent No. US 5904720 A.92 In September, 2008, the 
Australian Orthopaedic Association National Joint Replacement 
Registry was reporting that this device had a significantly higher 
than expected revision rate.93 DePuy recalled the device voluntarily 
in 2009 in Australia for “declining demand.”94 The National Joint 
Registry of England and Wales reported in 2010 that the five-year 
revision rate for this device was five times higher than for all other 
devices combined at thirteen percent, and as a result of the data from 
England and Wales, DePuy completely withdrew the product from 
the world market in 2010.   
                                                 
91 See Brent M. Ardaugh, et. al. The 510(k) Ancestry of a Metal-on-
Metal Hip Implant, N ENGL J MED 368:2, pp 97-100, Jan 10, 2013. 
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 It is a quirk of law that allows devices to be evaluated for 
510(k) approval by the FDA, as long as the substantially equivalent 
predicates have not been withdrawn from the market because of 
court order or because of FDA directed recall.95 
 Inherent in the nature of the 510(k) approval process for 
these various metal-on metal hip implants is the introduction of the 
issue referred to as “predicate creep.” Predicate creep can readily 
occur during the 510(k) process when each new device is changed 
slightly as compared to its previously approved predicate substantial 
equivalent. As each new substantially equivalent device is slightly 
altered and submitted for approval, the result can be, after several 
permutations, that the current device submitted as a substantial 
equivalent bears little resemblance to the original parent device. This 
is precisely the problem demonstrated in the current generation of 
metal-on-metal hip arthroplasties.96   
                                                 
92 See supra note 63. 
93 Ardaugh, supra note 90. 
94 Id. at 98. 
95 Institute of Medicine, Medical devices and the public’s health: the 
FDA 510(k) clearance process at 35 years, Washington DC: 
National Academies Press, 2011. 
96 See Arianne Freeman, Predicate Creep: The Danger of Multiple 
Predicate Devices, 23 ANNALS HEALTH L. ADVANCE 
DIRECTIVE 127, 2014. 
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 In a 2014 article, Arianne Freeman actually advocates for 
complete elimination of the 510(k) approval process, arguing that the 
process “shifts device testing from the clinical trial setting to the 
public market place, thus unethically veering potential risks to the 
patients.”97  In fact, “Congress had always intended class III devices 
to undergo PMA, and in 1990, it directed the [FDA] to establish a 
schedule to finish the transition to PMAS for all devices that were to 
remain in class III,” but the FDA had, as of December 2012, not 
completed the transition requested by Congress.98   
 In more recent developments, however, the FDA has 
instructed prosthetic hip manufacturers that they must seek 
premarket approval for metal-on-metal hip components with 
acetabular components held to the bone either by bone cement or 
held in press-fit fashion.  This order went into effect in February, 
2016.99 
 Congress and the FDA have indicated that there is an 
increasing desire to eliminate the 510(k) approval process because of 
the inherent problems discussed  above regarding substantial 
equivalence and the potential development of predicate creep.100 
What has not been addressed, however, is the disconnect created by 
granting a patent based on utility, novelty, and non-obviousness to a 
medical device that is subsequently submitted for FDA approval 
based on substantial equivalence to a predicate device. 
V. Economic Impact of ASR Hip Recalls 
                                                 
97 Id.; see Deborah Cohen, How safe are metal-on-metal hip 
implants?, 1(4) BRIT. MED. J., Feb. 28, 2012, 
http://www.bm.com/content/344/bmj.e1410.pdf%2Bhtml 
[hereinafter How safe are metal-on-metal hip implants?]. 
98 See Ardaugh, supra note 90; see also Freeman, supra note 95. 
99 U. S. FOOD & DRUG ADMINISTRATION, 
https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedure
s/ImplantsandProsthetics/MetalonMetalHipImplants/ucm241769.ht
m (last visited on Apr. 19, 2018). 
100 Id.; see also Freeman, supra note 95. 
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 The voluntary recalls of the ASR hip by DePuy and of other 
metal-on-metal hips has resulted in extended product liability 
litigation and an enormous economic burden to society and to the 
medical device manufacturing community. The large numbers of 
product liability related lawsuits have placed a large burden on the 
United States judicial system. 
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 As a result of the clinical failures of the ASR hip and the 
subsequent voluntary recalls by Johnson & Johnson, DePuy’s parent 
company, multiple product liability lawsuits were filed. Many of the 
plaintiffs’ cases have been consolidated either into multidistrict 
litigation or into class action lawsuits.101 Furthermore, a search on 
one of the online legal services for “DePuy ASR” will result in 
multiple citations for various pending or resolved actions across the 
country. While the actual number of plaintiffs is difficult to 
ascertain, approximately 10,000 individuals in two different 
settlements will recover just over four billion dollars.102 While this is 
an estimated settlement cost to DePuy, this figure does not take into 
account the other millions of dollars spent across the country in 
pursuit of these legal actions. Furthermore, it does not take into 
consideration the countless hours of time spent by attorneys for both 
sides, judges and their staffs, and the actions required by the various 
plaintiffs and defendant representatives. The actual expenses 
including various lost wages and pain and suffering costs could 
extend into the tens of billions of dollars.   
                                                 
101 See, eg. 13 No. 8 Westlaw Journal Nursing Home 8, October 8, 
2010, California Man Files Class Suit Over Recalled Depuy Hip 
Implants; see also, eg U.S. Judicial Panel on Multidistrict Litigation, 
MDL Statistics Report-Distribution of Pending MDL Dockets by 
District (Sept. 16, 2017) 
http://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Docke
ts_By_District-September-15-2017.pdf. 
102 Barry Meier, Maker Aware of 40% Failure in Hip Implant, N.Y. 
TIMES (Jan. 22, 2013), 
http://www.nytimes.com/2013/01/23/business/jj-study-suggested-
hip-device-could-fail-in-thousands-more.html; see also Jef Feeley 
and David Voreacos, J & J Said to Reach $4 Billion Deal to Settle 
Hip Lawsuits, BLOOMBERG (Nov. 13, 2013), 
https://www.bloomberg.com/news/articles/2013-11-12/j-j-said-to-
reach-4-billion-deal-to-settle-hip-lawsuits. 
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 One must remember that the ASR hip recall and its resultant 
litigation was only one of several recalls involving either different 
manufacturers, such as Stryker or Zimmer, or other product lines 
belonging to DePuy, such as the Pinnacle hip which is also 
manufactured by DePuy. The Minneapolis Star Tribune reported that 
Stryker had reached a $1.4 billion settlement in a separate but related 
lawsuit involving a different type of metal-on-metal articulation 
between the femoral stem and the femoral neck of hip implants.103 
 While hip implant manufacturers may have been able to 
decrease costs by pursuing 510(k) approval instead of PMA 
approval, it would appear that the rush to get implants to market for 
competition purposes has resulted in a substantially larger cost to the 
manufacturers than would have otherwise been realized. 
Furthermore, the actions of the device manufacturers effectively 
created a large unmonitored clinical trial that shifted the burden and 
the risk to the population of individuals requiring a total hip 
arthroplasty.  
VI. Public Policy Considerations 
 Given the unfortunate events surrounding this regulation, 
implantation, and subsequent recall of the DePuy’s ASR hip, the 
natural inclination and visceral response would be to try to effect 
changes that would prevent a similar occurrence in the future. This 
is, perhaps, more easily suggested than accomplished. 
 The Constitutional history of the United States and the 
legislative history of Congress have confirmed that the protection of 
intellectual property rights via Article I, Section 8, Clause 8, as well 
as the availability of transient, limited monopolies through the patent 
process, enumerated in the most recent America Invents Act, will be 
preserved. If inventors and scientists and industry are dis-
incentivized to be innovative, then it is likely that progress in 
medical device development will diminish. 
                                                 
103 Joe Carlson, $1.4 billion settlement announced in artificial hip 
litigation, STAR TRIBUNE (Dec. 14, 2014), 
http://www.startribune.com/nov-3-1-4-billion-settlement-in-
artificial-hip-litigation/281375461/. 
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 That being said, some form of regulation and safety 
assessment still needs to be performed whether by a governmental 
agency such as the FDA or by some other private entity to ensure 
that medical devices that are made available to the public are safe 
and effective. No regulatory scheme will be able to prevent 
mechanical failures of medically implanted prosthetic devices such 
as total hip arthroplasty components. As a result of the events 
involving the ASR and other metal-on-metal hips, the FDA has 
abolished the 510(k) mechanism and mandated PMA evaluation for 
certain types of hips with metal-on-metal bearings.104 While this 
action may result in more thorough, short term clinical evaluation 
with the potential for increased safety for the public, it is likely to 
have two other effects. First it is likely to deter scientists and 
manufacturers involved in the development of prosthetic hips from 
pursuing research along these lines—especially when considering 
the price tag of the evolving litigation relating to such implants. 
Second, should scientists and developers pursue this “useful art”, the 
costs of research, regulatory approval and defense against potential 
litigation are likely to prove to be significantly more, if not 
prohibitively expensive. As is true in the nature of business 
transactions, this will result in the cost being passed along to the 
consumer, be it to the individual patient or to a corporate consumer 
such as a health care system or the federal government. 
                                                 
104 See supra note 100. 
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 It is a knee-jerk response to suggest that previously 
developed and marketed technologies that have fallen by the 
wayside due to suboptimal performance should be altogether 
abandoned.  The history of total joint arthroplasty specifically, and 
or orthopaedic surgery in general is comprised of similar procedures 
or technology that were not initially successful, were buried in the 
archives of history, and were subsequently resurrected in new, 
modified, more successful versions. For example, THA was 
previously associated with a disturbingly high infection rate as well 
as an unacceptable rate of hip instability, whereby the hip would 
dislocate from the socket after surgery. Multiple aspects of the 
procedure are notable for its success, but progressive technological 
developments have all contributed to the extreme success of the 
operation105—so much so that it was dubbed the “operation of the 
century.”106 If some of the regulatory processes had been made more 
stringent, and if some of the intellectual property protective benefits 
had been eliminated, it is unlikely that the success of the operation 
would have developed and advanced as much as it has in the last 
fifty years. 
VII. Possible Solutions to the Conundrum 
 Unravelling this spiderweb of overlapping regulation, 
unintended consequences, and seemingly conflicting purposes is not 
easy.  There are, however, some solutions to propose. 
                                                 
105 Important developments in THA include use of perioperative 
antibiotics, use of laminar flow operating rooms with special air 
handling characteristics, shorter operative times, smaller, less 
invasive incisions, and implant modification involving less invasive 
implants with more physiologically sized femoral heads. 
106 I.D. Learmonth ID, C. Young, C. Rorabeck, The Operation of the 
Century: Total Hip Replacement, 370(9597) LANCET, Oct. 27, 
2007 7:370(9597): 1508-19. 
41Published by Mitchell Hamline Open Access, 2018
                    CYBARIS®, AN INTELLECTUAL PROPERTY LAW REVIEW                              346 
 
 While monopolies have been distasteful—both to our English 
legal ancestors as manifested in the no Monopolies act, and to the 
Patent Office from its earliest days with Thomas Jefferson,107 it may 
be necessary to extend the length of patent protection.  Justice Story 
commented in Graham in 1966 “Technology [] has advanced—and 
with remarkable rapidity in the last fifty years. Moreover, the ambit 
of applicable art in given fields of science has widened by 
disciplines unheard of half a century ago.”108 Perhaps this advent of 
these new and previously unheard of technologies will necessitate an 
overhauling of the patent system more equipped to handle the 
complexities of this previously unheard of applicable art. 
 One possibility would be to develop a tiered patent system 
that grants patents of varying lengths—for example twenty, thirty-
five, and fifty years—to accommodate the complexity of obtaining 
more thorough regulatory evaluation and testing. 
 Another option would be to develop patent tracts for the 
various classes of medical devices such that items in Class I are 
evaluated for patents in a different fashion or with different criteria 
than Class III medical devices, which would be evaluated with a 
different set of criteria or different time frame. 
 Another way to manage this would be to delay the patent 
process or modify it until after the regulatory evaluation is 
completed. Pre-patent protection could still be provided by an 
application process that provides public notice to the scientific and 
manufacturing communities that prior art has been established. The 
potential limitation to this is that inventors and manufacturers are 
unlikely to invest the larger sums of money that will be required of 
product research, development and testing without the assurance that 
their intellectual property would be protected. 
                                                 
107 See Halpern, supra note 32; see also Graham v. John Deere Co. 
of Kansas City, 383 U. S. 1, 684, 688 where J. Clark noted 
“Jefferson, like other Americans, had an instinctive aversion to 
monopolies.” 
108 Graham at 694. 
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 The USPTO could review and grant patents that have 
fulfilled the requirements of utility, novelty, and non-obvious subject 
matter, but the lifetime of the patent could only be counted upon the 
technology’s completion of its regulatory approval process.   
 One way to solve the seeming conflict between requiring 
safety to fulfill the usefulness criteria of § 102 is to pursue a 
regulatory process similar to that currently in use in Europe. The 
European equivalence of the FDA’s PMA process is the CE mark 
(Conformite Europeenne) which allows a medical device to be 
marketed in all European countries.109 The CE mark requires proof 
of the device’s performance, whereas US FDA approval of a PMA 
application requires proof of the device’s safety and efficacy.110 This 
would avoid the perceived conflict of requiring the establishment of 
safety to provide for utility and would be in conformity with the 
Supreme Court’s decision in Brenner. One caveat is that given some 
of the recent high-profile device failures in the European Union, the 
European Union appears to be moving more toward a regulatory 
system reflecting that provided by the FDA.111 
                                                 
109 T. Maak, J. Wylie, supra note 65. 
110 Id.; DB Kramer, S Xu, and AS Kesselheim, Regulation of 
Medical Devices in the United States and European Union, N ENGL 
J MED 2012: 366(9): 848-855. 
111 D. Kramer, et. al. supra note 109. 
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 Yet another means of resolving this perceived conflict would 
be for developers of medical devices to abandon pursuing patent 
protection of their intellectual property. Instead, they could pursue 
trade secret protection. “An innovator might choose to protect 
information or an invention via trade secret instead of patent law 
because a trade secret holder will never have to disclose the 
information ‘as long as the information remains secret and meets 
other judicial criteria allowing for the preservation of its 
secrecy.’”112 Because there is no defined longevity of trade secret 
effectiveness, the length of time for FDA PMA approval would not 
be as restrictive to the potential lucrativeness of developing medical 
devices requiring long clinical trials. The downside to this proposal 
is the resulting introduction of another entirely separate statutory 
scheme under the Economic Espionage Act and the associated 
Defend Trade Secrets Act.113   
 A somewhat “Modest Proposal”114 would be to either 
eliminate the function of the USPTO patentability requirements or 
the FDA’s watchdog function. While this may give cause for great 
rejoicing among some members of the medical community, they 
would still have to admit begrudgingly that the FDA serves an 
essential function in safeguarding the health of U.S. citizens. 
                                                 
112 Robin J Effron, Trade Secrets, Extraterritoriality, and 
Jurisdiction, 51 WAKE FOREST L. REV. 765, 767, (Fall 2016); 
and Robin J. Effron, Secrets and Spies: Extraterritorial Application 
of the Economic Espionage Act and the TRIIPS Agreement, 78 
N.Y.U. L. REV. 1475, 1476-77 (2003). 
113 18 U.S.C §§ 1831 and 1839 (1996). 
114 Jonathan Swift, A Modest Proposal: For Preventing The Children 
of Poor People in Ireland From Being a Burden to Their Parents or 
Country, and For Making Them Beneficial to the Public, (1729). 
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 Perhaps the best solution involves a two-pronged change to 
the regulation of these types of implantable devices and their 
associated protection as intellectual property under patent law. First, 
the FDA should subdivide Class III devices into, say, Class IIIA and 
Class IIIB devices and require all Class III devices to undergo PMA. 
Class IIIA would be those devices that can have their clinical safety 
established relatively quickly under PMA—within, say, twenty-four 
months. Class IIIB would be those devices that take longer than 
twenty-four months to establish clinical safety by pre-market 
analysis. 
 The current patent structure would remain the same for Class 
IIIA devices. However, for Class IIIB devices, the patent structure 
could be modified such that the patent is applied for with the 
initiation of the pre-market analysis for the device, but the actual 
granting of the twenty-year patent protection occurs only upon 
completion of pre-market analysis be it at two, five, or however 
many years.   
 There are several benefits to this proposal. First, the clinical 
devices that require a longer time to establish clinical safety, and 
therefore usefulness, would all undergo PMA rather than 510(k) 
FDA approval. Second, inventors would be assured their inventions 
would receive patent protection for a full twenty years. Finally, from 
a public policy perspective, patients could be assured that the 
implants with which they are treated have undergone the more 
rigorous PMA establishment of clinical safety, and the nation and 
economy would benefit by encouraging designers to pursue the 
development of such implants for the benefit of the populace with 
the knowledge that their intellectual property would be protected for 
the full patent term. 
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